Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 4 | Journal for ImmunoTherapy of Cancer

Figure 4

From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Figure 4

The waterfall plot demonstrates the percent change of measurements by two criteria at the first follow-up scan. Dark gray bars represent the percent changes by irRC simulating RECIST1.0, and light gray bars represent the percent changes by irRC simulating RECIST1.1. Dashed lines at +20% and -30% represent the cut-off values for progressive disease and partial response, respectively. 5 patients with discordant assessment are marked with asterisks (*).

Back to article page